158 related articles for article (PubMed ID: 37693166)
1. Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer.
Xiong H; Li Y
Am J Cancer Res; 2023; 13(8):3559-3570. PubMed ID: 37693166
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study.
Wang C; Wang Z; Zhao Y; Wang F
J Gastric Cancer; 2023 Apr; 23(2):328-339. PubMed ID: 37129156
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
Wang Z; He T; Yu D; Qin X; Geng A; Yang H
Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
[TBL] [Abstract][Full Text] [Related]
4. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.
Xu C; Xie X; Kang N; Jiang H
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
Lin JX; Tang YH; Zheng HL; Ye K; Cai JC; Cai LS; Lin W; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Zheng CH; Li P; Huang CM
Nat Commun; 2024 Jan; 15(1):41. PubMed ID: 38167806
[TBL] [Abstract][Full Text] [Related]
7. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer.
Zhang Y; Zhang B; Yang J; Zhang J; Zhang W
Cancer Manag Res; 2021; 13():2279-2286. PubMed ID: 33732020
[TBL] [Abstract][Full Text] [Related]
8. Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.
Pan D; Liu D; Liang L; Shen T; Shi C; Qin H
Front Oncol; 2022; 12():863392. PubMed ID: 35664730
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC.
Zhou PZ; Gao L; Wu W; Hao YX
Pak J Med Sci; 2021; 37(7):1890-1895. PubMed ID: 34912413
[TBL] [Abstract][Full Text] [Related]
10. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study.
Zhang X; Zhang C; Hou H; Zhang Y; Jiang P; Zhou H; Wang L; Zhou N; Zhang X
Transl Oncol; 2023 May; 31():101657. PubMed ID: 36934638
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study.
Yu D; Wang Z; He T; Yang L
Front Surg; 2022; 9():842828. PubMed ID: 35647008
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial.
Guo H; Ding P; Sun C; Yang P; Tian Y; Liu Y; Lowe S; Bentley R; Li Y; Zhang Z; Wang D; Li Y; Zhao Q
Front Oncol; 2022; 12():927781. PubMed ID: 36091139
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
Hou X; Shi X; Luo J
Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of neoadjuvant apatinib in combination with capecitabine and oxaliplatin for the therapy of locally advanced colorectal cancer: A retrospective study.
Zhang T; Peng X; Li G; Yan L; Zhang A; Jia X
Oncol Lett; 2024 May; 27(5):201. PubMed ID: 38516687
[TBL] [Abstract][Full Text] [Related]
17. Apatinib plus chemotherapy is associated with an improved tumor response, survival and tolerance compared with chemotherapy alone for advanced lung adenocarcinoma treatment.
Ye H; Yu W; Ni Y; Bao X; Zhang X; Li Y; Chen A; Li J; Zheng L
Oncol Lett; 2024 May; 27(5):194. PubMed ID: 38495832
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
19. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhao J; He M; Li J; Li D; Zhao Y; Li X; Zhang X; Chen X; Liu Y; Zhao L
Cancer Biother Radiopharm; 2022 May; 37(4):324-331. PubMed ID: 34524004
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study.
Wang X; Huang J; Huang H; Liu Y; Ji C; Liu J
Invest New Drugs; 2023 Aug; 41(4):579-586. PubMed ID: 37368088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
